| Staten Island Oral & Maxillofacial Surgery | |
|
256 Mason Ave # C Staten Island NY 10305-3408 | |
| (718) 226-1251 | |
| (718) 226-1252 |
| Full Name | Staten Island Oral & Maxillofacial Surgery |
|---|---|
| Speciality | Dentist |
| Location | 256 Mason Ave # C, Staten Island, New York |
| Authorized Official Name and Position | David C Hoffman (PRESIDENT) |
| Authorized Official Contact | 7182261251 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Staten Island Oral & Maxillofacial Surgery 256 Mason Ave # C Staten Island NY 10305-3408 Ph: (718) 226-1251 | Staten Island Oral & Maxillofacial Surgery 256 Mason Ave # C Staten Island NY 10305-3408 Ph: (718) 226-1251 |
| NPI Number | 1316217763 |
|---|---|
| Provider Enumeration Date | 01/03/2012 |
| Last Update Date | 01/03/2012 |
| Medicare PECOS PAC ID | 4486821709 |
|---|---|
| Medicare Enrollment ID | O20120126000740 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316217763 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223S0112X | Dentist - Oral And Maxillofacial Surgery | 033292 (New York) | Primary |
| Provider Name | Mark Stein |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1093778102 PECOS PAC ID: 5991695116 Enrollment ID: I20040319000150 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Provider Name | Joshua D Segal |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1154595734 PECOS PAC ID: 4688829328 Enrollment ID: I20130301000128 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Provider Name | Steve Yusupov |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1982991485 PECOS PAC ID: 9032482104 Enrollment ID: I20170912001720 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Provider Name | Lydia J Lam |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1649542523 PECOS PAC ID: 5395085567 Enrollment ID: I20190326001004 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Provider Name | Emad Abdou |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1174914766 PECOS PAC ID: 6608269147 Enrollment ID: I20220207000388 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
| Provider Name | Mark Goodenough |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1154858033 PECOS PAC ID: 6800240433 Enrollment ID: I20230929001677 |
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
News Archive
Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.
Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.
Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.
The National Institutes of Health announced on Wednesday the award of a new research grant to discover, characterize and validate complex molecular networks and candidate genes that influence susceptibility to cognitive decline and Alzheimer's disease.
› Verified 8 days ago
Village Green Dental Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 337 Hampton Grn, Staten Island, NY 10312 Phone: 718-948-0870 | |
2791 Richmond Llc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2791 Richmond Avenue, Suite 2, Staten Island, NY 10314 Phone: 718-400-9002 | |
Staten Island Mall Dental, P.c. Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2655 Richmond Avenue, 2220, Staten Island, NY 10314 Phone: 718-982-5500 Fax: 718-982-5554 | |
Smiles Forever Dental Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 4255 Amboy Rd, Staten Island, NY 10308 Phone: 718-682-3373 | |
Small World Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 6795 Hylan Blvd, Staten Island, NY 10309 Phone: 718-967-2412 Fax: 718-554-4515 | |
Kids Dental Of Staten Island, Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1839 N Railroad Ave, Staten Island, NY 10306 Phone: 718-667-5437 | |
Cool Dentist Pllc Dental Clinic Medicare: Medicare Enrolled Practice Location: 205 Port Richmond Ave, Staten Island, NY 10302 Phone: 718-727-2555 |